發(fā)布時(shí)間：2018-12-31 13:24

【摘要】：背景與目的:原發(fā)性支氣管肺癌(簡(jiǎn)稱(chēng)肺癌)在目前惡性腫瘤中發(fā)病率和死亡率最高且較為常見(jiàn),本文目的在于回顧性研究2005年與2015年吉林大學(xué)中日聯(lián)誼醫(yī)院胸外科患者肺癌臨床特征及診治方法,為肺癌患者的早期診斷及早期治療提供依據(jù)。方法:收集2005年與2015年吉林大學(xué)中日聯(lián)誼醫(yī)院胸外科住院患者中首診診斷為肺癌的病例,基于兩組患者的不同就診模式、平均就診時(shí)間、合并其它疾病、肺癌合并其它類(lèi)型癌的雙原發(fā)癌、家族惡性腫瘤病史、肺癌發(fā)生位置,以及初診主要治療手段等對(duì)收集的臨床資料進(jìn)行了對(duì)比和分析。結(jié)果:收集了有明確組織學(xué)病理依據(jù)的原發(fā)性支氣管肺癌患者病例共計(jì)1610例,其中2005年410例,2015年1200例。在2005年至2015年這10年中因體檢發(fā)現(xiàn)問(wèn)題而就診的原發(fā)性支氣管肺癌患者所占比例提高(6.3%vs18.2%,p0.001),患者平均就診時(shí)間縮短(p0.001),有一級(jí)親屬的惡性腫瘤史的肺癌患者數(shù)增多(5.6%vs15.8%,p0.001);NSCLC(非小細(xì)胞肺癌)患者IV期和Ia期所占比例顯著上升(Ia期:1.5%vs5.4%,p0.001;IV期:31.5%vs38.6%,p0.001),IIIa期腫瘤所占比例明顯降低(24.5%vs12.6%,p=0.002);患NSCLS(非小細(xì)胞肺癌)的患者在治療上初診診行化療治療的比例升高(33.4%vs53.6%,p=0.008),IIIa期初診選擇行手術(shù)治療的患者所占比例顯著提高(47.6%vs72.5%,p=0.002)。結(jié)論:2005至2015這十年間原發(fā)性支氣管肺癌患者的一部分臨床特征已經(jīng)發(fā)生了顯著的變化,以這些變化為基礎(chǔ)制定出更合理的方案對(duì)肺癌的預(yù)防、診斷和治療及降低肺癌發(fā)病率,延長(zhǎng)生存期有一定意義。
[Abstract]:Background & objective: primary bronchial lung cancer (lung cancer) has the highest morbidity and mortality among malignant tumors. The purpose of this paper is to study retrospectively the clinical features, diagnosis and treatment of lung cancer in the thoracic surgery department of Sino-Japanese Friendship Hospital of Jilin University in 2005 and 2015, so as to provide the basis for early diagnosis and treatment of lung cancer patients. Methods: the first diagnosed lung cancer cases were collected from thoracic surgery inpatients of Sino-Japanese Friendship Hospital of Jilin University in 2005 and 2015. The clinical data of double primary carcinoma with other types of lung cancer, family malignant tumor history, location of lung cancer, and primary treatment were compared and analyzed. Results: a total of 1610 cases of primary bronchial lung cancer with clear histopathological basis were collected, including 410 cases in 2005 and 1200 cases in 2015. Between 2005 and 2015, the proportion of patients with primary bronchial lung cancer who were diagnosed by medical examinations increased (6.3 vs 18.2 / p0.001), and the average duration of visits was shortened (p0.001), The number of lung cancer patients with a history of malignant tumor in first-degree relatives increased (5.6 vs 15.8cm, p0.001); The proportion of IV and Ia in patients with NSCLC (non-small cell lung cancer) increased significantly (Ia: 1.5 vs 5.4 and P 0.001); IV stage: the proportion of tumor in 31.5% vs 38.6% was significantly lower than that in), IIIa stage (24.5vs12.6%, p0.002). The proportion of patients with NSCLS (non-small cell lung cancer) receiving chemotherapy at first visit was significantly increased (33.4% vs 53.6%, p 0.008), IIIa), and the proportion of patients undergoing surgical treatment was significantly increased (47.6 vs 72.5%). P0. 002). Conclusion: significant changes have taken place in some clinical features of patients with primary bronchial lung cancer during the past ten years from 2005 to 2015. Based on these changes, a more reasonable program has been developed to prevent, diagnose and treat lung cancer and to reduce the incidence of lung cancer. Prolonging the survival time has certain significance.
【學(xué)位授予單位】：吉林大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R734.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 拾景海;26例X線胸片隱蔽肺癌臨床分析[J];江蘇醫(yī)藥;2000年03期

2 史鶴玲,朱允中,徐麗焱,劉哲,唐俊舫,游永紅,孟棄逸,張新勇;國(guó)產(chǎn)替尼泊甙治療肺癌臨床研究[J];北京醫(yī)學(xué);2001年05期

3 焦克崗,陳宏;1108例肺癌臨床病理分析[J];新疆醫(yī)科大學(xué)學(xué)報(bào);2002年01期

4 丁文柏;65例青年人肺癌臨床分析[J];醫(yī)學(xué)文選;2002年01期

5 ;部分肺癌臨床科研機(jī)構(gòu)網(wǎng)址[J];中國(guó)肺癌雜志;2008年01期

6 ;部分肺癌臨床科研機(jī)構(gòu)網(wǎng)址[J];中國(guó)肺癌雜志;2008年02期

7 ;部分肺癌臨床科研機(jī)構(gòu)網(wǎng)址[J];中國(guó)肺癌雜志;2010年07期

8 ;部分肺癌臨床科研機(jī)構(gòu)網(wǎng)址[J];中國(guó)肺癌雜志;2010年08期

9 ;部分肺癌臨床科研機(jī)構(gòu)網(wǎng)址[J];中國(guó)肺癌雜志;2010年11期

10 ;部分肺癌臨床科研機(jī)構(gòu)網(wǎng)址[J];中國(guó)肺癌雜志;2010年12期

相關(guān)會(huì)議論文 前10條

1 肖貴華;吳建平;;355例肺癌臨床分析[A];中華醫(yī)學(xué)會(huì)第七次全國(guó)呼吸病學(xué)術(shù)會(huì)議暨學(xué)習(xí)班論文匯編[C];2006年

2 毛友生;赫捷;高燕寧;程書(shū)鈞;張德超;;肺癌臨床診療難題與分子生物學(xué)特性的關(guān)系[A];中華醫(yī)學(xué)會(huì)第六次全國(guó)胸心血管外科學(xué)術(shù)會(huì)議論文集（胸外科分冊(cè)）[C];2006年

3 劉洪吉;劉蘭香;吳淑琴;劉宸隆;馮娟;;肺積消A、B、C治療肺癌臨床觀察和抗肺癌作用的實(shí)驗(yàn)研究[A];第八屆全國(guó)中西醫(yī)結(jié)合腫瘤學(xué)術(shù)會(huì)議論文集[C];2000年

4 黃寶生;;青年女性肺癌臨床CT診斷[A];中華醫(yī)學(xué)會(huì)第十三屆全國(guó)放射學(xué)大會(huì)論文匯編（下冊(cè)）[C];2006年

5 趙培`，

本文編號(hào)：2396643